Introducing New Contributor Jorge Contreras

Jorge Contreras.Jorge Contreras is joining Bill of Health as a regular contributor.

Jorge L. Contreras is a Presidential Scholar and Professor of Law at the University of Utah with an adjunct appointment in the Department of Human Genetics. His research focuses on intellectual property, technical standards and science policy, and he is one of the co-founders of the Open COVID Pledge, a framework for contributing intellectual property to the COVID-19 response. Professor Contreras is the editor of six books and the author of more than 100 scholarly articles and chapters appearing in scientific, legal and policy journals including Science, Nature, Georgetown Law Journal, NYU Law Review, Iowa Law Review, Harvard Journal of Law and Technology and Antitrust Law Journal.  He has served as a member of the National Institutes of Health (NIH) Council of Councils, the Advisory Councils of the National Human Genome Research Institute (NHGRI) and the National Center for Advancing Translational Sciences (NCATS), and as the Co-Chair of the National Conference of Lawyers and Scientists. He is a graduate of Harvard Law School (JD) and Rice University (BSEE, BA).

Stacks of books against a burgundy wall

Announcing The Journal of Philosophy of Disability 

The Journal of Philosophy of Disability (JPD) is a new journal devoted to the philosophical study of disability.

Disability is central to human life. As the slogan from disability studies goes: “disability is everywhere, once you know how to look for it.” After a steady stream of scholarship from the 1990s onward, work in the field of philosophy of disability has expanded exponentially. Despite this explosion, there has never been a peer-reviewed journal devoted to scholarship in the field of philosophy of disability. Until now.

Read More

a pill in place of a model globe

How Do We Arrive at Fair Pricing for COVID-19 Therapies?

By Padmashree Gehl Sampath

As the search for COVID-19 treatments and vaccines continues, questions of pricing and access are beginning to emerge.

How can pharmaceutical companies determine fair prices for these therapies? And how can they ensure that all those who need these treatments are able to access them? These are valid concerns in the current global pharmaceutical landscape, where in recent years, soaring drug prices have been an issue for almost all governments.

Read More

Bill of Health is Looking to Amplify BIPOC Voices

Bill of Health strongly affirms that black lives and black voices matter, and we want to do more to feature and amplify the work of BIPOC scholars and students.

Accordingly, we are looking for new, regular contributors to Bill of Health, as well as guest bloggers. Regular contributors generally publish between five and 12 posts per year. Guest bloggers typically contribute two to five posts over the course of a one-month period. We welcome news, commentary, and scholarship in the fields of health law policy, biotechnology, and bioethics. Posts are typically 750 words in length.

If you are interested in becoming a regular contributor or guest blogger, please email editor-in-chief Chloe Reichel.

Budapest, Hungary.

Hungary’s Response to COVID-19 Vastly Expands Executive Power

By Csaba Győry

Hungary was one of the first countries in Europe to introduce restrictions in order to flatten the curve of COVID-19 infections.

Policy wise, the restrictions overall were similar to those of other European countries. The legal basis for these restrictions, however, has proven very controversial because of the extremely broad sway it provides the executive, and has received a great deal of attention from EU institutions, scholars, and the press.

This is the conundrum of the Hungarian response to COVID-19: an almost unlimited authorization for the executive to rule by decree, which, at the same time, was used relatively sparingly and in a broadly similar manner as in other EU countries.

Read More

Special Pandemic Issue of the Journal of Law and the Biosciences

On March 24, 2020, the Journal of Law and the Biosciences, jointly run by Duke UniversityHarvard University Law School, and Stanford University, put out a call for essays and articles on governance in a time of pandemic. Between April 22 and May 28, it published 25 articles, all of which are available at the Journal’s website free of charge. We expect that more than 20 additional pieces will join them over the next month or so. The following is a regularly updated list, organized by date and time of publication, of what has been published in that special issue to date.

Read More

Pile of colorful pills in blister packs

Could Vioxx Make a Comeback? Recalled Drug Receives Orphan Designation

By Blake N. Shultz and Gregory Curfman

Despite a troubling history, rofecoxib (Vioxx) may be making a comeback.

The voluntary withdrawal of rofecoxib (Vioxx) from the market in September 2004 marked the end of a controversial era for a once highly profitable and widely used drug. It also marked the beginning of years of high-profile product-liability litigation that would cost Merck billions.

Read More